Corrigendum to "Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial" [Eur. Urol. 86 (2024) 552-562].
Publication
, Journal Article
Armstrong, AJ; Sartor, O; de Bono, J; Chi, K; Fizazi, K; Krause, BJ; Herrmann, K; Rahbar, K; Tagawa, ST; Saad, F; Beer, TM; Wu, J; Mirante, O ...
Published in: Eur Urol
June 2025
Duke Scholars
Published In
Eur Urol
DOI
EISSN
1873-7560
Publication Date
June 2025
Volume
87
Issue
6
Start / End Page
738 / 739
Location
Switzerland
Related Subject Headings
- Urology & Nephrology
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Armstrong, A. J., Sartor, O., de Bono, J., Chi, K., Fizazi, K., Krause, B. J., … Morris, M. J. (2025). Corrigendum to "Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial" [Eur. Urol. 86 (2024) 552-562]. Eur Urol, 87(6), 738–739. https://doi.org/10.1016/j.eururo.2025.03.008
Armstrong, Andrew J., Oliver Sartor, Johann de Bono, Kim Chi, Karim Fizazi, Bernd J. Krause, Ken Herrmann, et al. “Corrigendum to "Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial" [Eur. Urol. 86 (2024) 552-562].” Eur Urol 87, no. 6 (June 2025): 738–39. https://doi.org/10.1016/j.eururo.2025.03.008.
Armstrong AJ, Sartor O, de Bono J, Chi K, Fizazi K, Krause BJ, et al. Corrigendum to "Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial" [Eur. Urol. 86 (2024) 552-562]. Eur Urol. 2025 Jun;87(6):738–9.
Armstrong, Andrew J., et al. “Corrigendum to "Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial" [Eur. Urol. 86 (2024) 552-562].” Eur Urol, vol. 87, no. 6, June 2025, pp. 738–39. Pubmed, doi:10.1016/j.eururo.2025.03.008.
Armstrong AJ, Sartor O, de Bono J, Chi K, Fizazi K, Krause BJ, Herrmann K, Rahbar K, Tagawa ST, Saad F, Beer TM, Wu J, Mirante O, Morris MJ. Corrigendum to "Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial" [Eur. Urol. 86 (2024) 552-562]. Eur Urol. 2025 Jun;87(6):738–739.
Published In
Eur Urol
DOI
EISSN
1873-7560
Publication Date
June 2025
Volume
87
Issue
6
Start / End Page
738 / 739
Location
Switzerland
Related Subject Headings
- Urology & Nephrology
- 3202 Clinical sciences
- 1103 Clinical Sciences